Blood Cancers | Tumor

FDA Grants Fast Track Designation for Azer-Cel in Lymphoma Subset

March 21st 2025, 4:00pm

Article

FDA grants fast track designation to azer-cel, an allogeneic CAR T-cell therapy, for relapsed or refractory diffuse large B-cell lymphoma.

Darzalex Plus Revlimid Improves Outcomes in Newly Diagnosed Myeloma

March 18th 2025, 9:00pm

Article

Darzalex and Revlimid maintenance resulted in superior outcomes versus Revlimid alone following autologous stem cell transplantation in multiple myeloma.

Orca-T Doubles Graft-Versus-Host Disease-Free Survival in Leukemia

March 18th 2025, 4:00pm

Article

Treatment with the T-cell immunotherapy Orca-T improved survival free of moderate-to-severe chronic graft-versus-host disease across leukemia subtypes.

Bexobrutideg Receives Orphan Drug Designation in Waldenström Macroglobulinemia

March 17th 2025, 7:00pm

Article

Bexobrutideg, a bioavailable agent, was granted orphan drug designation by the FDA for Waldenström macroglobulinemia, a type of non-Hodgkin's lymphoma.

A Picture is Worth Ten Thousand Words When it Comes to Cancer

March 17th 2025, 5:00pm

Article

Years after losing my brother to Hodgkin’s lymphoma, I learned something about how he felt facing a terminal diagnosis by studying an old Polaroid.

Bringing Together the CAR T-Cell Therapy Community

March 12th 2025, 7:26pm

Article

It’s easy to think of scientific researchers as existing in a vacuum.

Nutrition is Key Following a Cancer Diagnosis

March 12th 2025, 7:14pm

Article

Nutrition is a challenge for many patients with cancer.

The Leukemia & Lymphoma Society is Helping Patients With Medial Debt

March 12th 2025, 7:01pm

Article

Cancer is one of the most expensive medical conditions to treat in the U.S.

JAK Inhibitors Reduce Thromboembolic Risk in Myeloproliferative Neoplasm Therapy

March 11th 2025, 3:38pm

Article

JAK inhibitor treatment is associated with a reduction in risk of thromboembolic events for patients with myeloproliferative neoplasms.

FDA Accepts Ordspono Resubmission in R/R Follicular Lymphoma Treatment

March 3rd 2025, 4:00pm

Article

The FDA has accepted the resubmission of the BLA of Ordspono for review in relapsed/refractory follicular lymphoma following previous systemic therapy.